Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Amgen will pay Micromet $14 million up front to apply the Rockville, Md.-based biotech firm’s BiTE antibody technology against three solid-tumor targets. Amgen has the right to develop BiTE antibodies against two of the targets. It will cover all the program’s R&D costs, which the companies say could run up to $35 million. Micromet’s BiTE antibodies bind T cells to tumor cells, prompting cell death as well as the proliferation of more T cells at the tumor site.
This article has been sent to the following recipient: